Latest Publications

Featured Article

Blood Journal. 24/07/2019

Phase 1 study of selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

Constantine Si Lun Tam, Judith Trotman, Stephen Opat, Jan A Burger, Gavin Cull, David J Gottlieb, Rosemary Anne Harrup, Patrick Johnston, Paula Marlton, Javier Munoz, John F. Seymour, David R Simpson, Alessandra Tedeschi, Rebecca Elstrom, Yiling Yu, Zhiyu Tang, Lynn Han, Jane Huang, William Novotny, Lai Wang and Andrew W. Roberts

Link to online journal article

PDF Article

---

This trial shows that zanubrutinib, a tablet taken twice daily, is very active in chronic lymphocytic leukaemia. The response rates were very high and the CLL came under good control in nearly all the patients. The good news for patients is that zanubrutinib was well tolerated with very few having to stop the tablets due to side-effects. While longer follow-up is needed, most patients remain on zanubrutinib with their CLL under very good control.

More Publications

• Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic.
  Source: Dr Chan CheahPublished on 2020-05-18
• High rate of durable remissions post autologous stem cell transplantation for core-binding factor acute myeloid leukaemia in second complete remission.
  Source: Dr Julie CrawfordPublished on 2020-05-08
• A consensus statement on the use of biosimilar medicines in hematology in Australia.
  Source: Dr Chan CheahPublished on 2020-04-15
• Potentials, challenges and future of chimeric antigen receptor T-cell therapy in non-Hodgkin lymphomas.
  Source: Dr Chan CheahPublished on 2020-03-20
• EBV-associated diffuse large B cell lymphoma arising within atrial myxoma in an immunocompetent patient can be treated successfully with surgery alone.
  Source: Dr Carolyn GrovePublished on 2020-02-29
• Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.
  Source: Dr Chan CheahPublished on 2020-02-07
• Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients.
  Source: Dr Chan CheahPublished on 2020-02-06
• Mantle cell lymphoma – where precision medicine based on response-adapted treatment strategies could show its full worth.
  Source: Dr Chan CheahPublished on 2020-01-31
• An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement.
  Source: Dr Chan CheahPublished on 2019-12-07
• An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement.
  Source: Dr David JoskePublished on 2019-12-07
• An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement.
  Source: Dr Gavin CullPublished on 2019-12-07
• Clinical Oncology Society of Australia position statement on cancer survivorship care.
  Source: Dr David JoskePublished on 2019-11-28
• Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines.
  Source: Dr Chan CheahPublished on 2019-11-15
• Marginal zone lymphoma causing accelerated progression of chronic kidney disease.
  Source: Dr Gavin CullPublished on 2019-11-14
• Author reply.
  Source: Dr Chan CheahPublished on 2019-10-12

Older posts